Colonial River Investments LLC Makes New $68,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Colonial River Investments LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, HoldingsChannel reports. The fund purchased 10,094 shares of the company’s stock, valued at approximately $68,000.

A number of other large investors have also recently bought and sold shares of RXRX. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp boosted its position in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares during the last quarter. Geode Capital Management LLC boosted its position in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares during the last quarter. Institute for Wealth Management LLC. acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $3,928,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after buying an additional 288,926 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Down 3.0 %

RXRX opened at $9.00 on Tuesday. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $15.74. The stock’s fifty day simple moving average is $7.59 and its 200 day simple moving average is $7.04. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $3.52 billion, a PE ratio of -5.88 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.